Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
PharmaTher Holdings Ltd ( (TSE:PHRM) ) has provided an announcement.
PharmaTher Holdings Ltd. has completed the sale of its Abbreviated New Drug Application for Ketamine Hydrochloride Injection USP, receiving an upfront cash payment and potential future milestone and profit-sharing payments. This move allows PharmaTher to concentrate on its long-acting injectable ketamine program, which aims to provide a more convenient and effective treatment option for neuropsychiatric disorders, potentially improving patient adherence and expanding market access.
Spark’s Take on TSE:PHRM Stock
According to Spark, TipRanks’ AI Analyst, TSE:PHRM is a Neutral.
PharmaTher Holdings Ltd. faces substantial financial hurdles, with no revenue and persistent losses weighing heavily on its stock score. However, recent positive corporate developments regarding FDA approval for ketamine could provide a significant future boost. Technical indicators are currently neutral, and valuation metrics reflect typical challenges for biotech firms in early stages. The potential regulatory approval is a key factor for future growth, but immediate financial struggles limit the current score.
To see Spark’s full report on TSE:PHRM stock, click here.
More about PharmaTher Holdings Ltd
PharmaTher Holdings Ltd. is a specialty life sciences company focused on unlocking the therapeutic potential of ketamine for neuropsychiatric disorders.
Average Trading Volume: 246,028
Technical Sentiment Signal: Sell
Current Market Cap: C$10.47M
For a thorough assessment of PHRM stock, go to TipRanks’ Stock Analysis page.